Clinical trials: Clinically Isolated Demyelinating Syndromes
Multiple Sclerosis - Relapsing Remitting, Clinically Isolated Syndrome, CNS Demyelinating
DTI in Children With Multiple Sclerosis
This is a prospective, non-randomised, non-blinded, single center study of children and adolescents with multiple sclerosis and clinically isolated syndrome to detect differences or early changes in diffusion-weighted imaging…
- Trial name
- NCT02361697
- Testing
- DTI-MRI
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital Muenster
Relapsing Forms of MS
Study of Diroximel Fumarate in the Real-World Setting
The primary objective of the study is to characterize the persistence to therapy in participants with relapsing forms of multiple sclerosis (RMS) treated with diroximel fumarate (DRF) in routine clinical practice.
- Trial name
- NCT04746976
- Testing
- Diroximel Fumarate
- Where
- 18 sites in United States
- Volunteers
- 75 people
- Sponsor
- Biogen
Multiple Sclerosis
Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis
The primary objective is to evaluate the feasibility of the Multiple Sclerosis Performance Test (MSPT) in a clinical care setting when used by participants with Multiple Sclerosis (MS).
- Trial name
- NCT03926637
- Testing
- Multiple Sclerosis Performance Test (MSPT)
- Where
- 33 sites in United States, Czechia and 4 more
- Volunteers
- 3,073 people
- Sponsor
- Biogen
Multiple Sclerosis
12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients
This is a 12-week study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of oral CS-0777 in patients with Multiple Sclerosis.
- Trial name
- NCT00616733
- Testing
- CS-0777 tablets
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Daiichi Sankyo
Radiologically Isolated Syndromes; Multiple Sclerosis
Comparison of Digital Biomarkers in Subjects With Radiologically Isolated Syndrome (RIS) and Multiple Sclerosis (MS) Patients With Clinically Normal Neurological Examination
Radiologically Isolated Syndrome (RIS) is the preclinical stage of Multiple Sclerosis (MS). It is the incidental discovery of white matter abnormalities on brain or spinal cord magnetic resonance imaging (MRI), whose shape…
- Trial name
- SPAM 3 (NCT07135752)
- Testing
- Precision assessment
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Multiple Sclerosis
Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b
The primary objective of the study is to evaluate the adherence to the treatment with interferon beta-1b, in patients diagnosed with isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), or secondary progressive…
- Trial name
- ADHERENCE (NCT03408093)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Volunteers
- 120 people
- Sponsor
- Bayer
Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination
Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
Multiple Sclerosis (MS) is a chronic inflammatory \& degenerative disease of the central nervous system (CNS) Recent data from the MS Base registry demonstrated an average delay of 152 - 215 days between first presentation and…
- Trial name
- AttackMS (NCT05418010)
- Testing
- Tyruko Injectable Product
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- Queen Mary University of London
Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis
This study will look at the blood and cerebrospinal fluid of consented participants who either have early stage multiple sclerosis (clinically isolated syndrome) or who have later stage (secondary progressive multiple sclerosis)…
- Conditions
- Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Clinically Isolated Syndrome
- Trial name
- NCT01737372
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- John F. Foley, MD
Multiple Sclerosis, MS, Clinically Isolated Syndrome
Cohort Study of Clinically Isolated Syndrome and Early Multiple Sclerosis
A majority of patients with multiple sclerosis initially presents with a single demyelinating event, e.g. in the optic nerves, brain, brainstem or spinal cord, referred to as a clinically isolated syndrome (CIS).
- Trial name
- CIS-COHORT (NCT01371071)
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Charite University, Berlin, Germany
Multiple Sclerosis, Clinically Isolated Syndrome (CIS)
Prebiotic vs Probiotic in Multiple Sclerosis
This is a randomized crossover-designed study to explore the immunologic effects of Prebiotics, as opposed to direct supplementation with beneficial bacteria (Probiotics) in the immune system of patients with MS and Clinically…
- Trial name
- MS (NCT04038541)
- Testing
- Prebiotics (Prebiotin Prebiotic Fiber Stick Pac), Probiotics (Visbiome®)
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Columbia University
Multiple Sclerosis, NMO Spectrum Disorder
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease…
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Radiologically Isolated Syndrome
- Trial name
- RECLAIM (NCT06280755)
- Where
- 3 sites in Czechia, Germany
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- icometrix
Multiple Sclerosis (MS), Relapsing-Remitting MS
Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease
This study intends to explore evolution of MSRV expression by analyzing the levels of MSRV transcripts in blood, as well as the levels of the MSRV-Env protein in serum of MS patients.
- Conditions
- Multiple Sclerosis (MS), Relapsing-Remitting MS, Primary Progressive MS, Secondary Progressive MS
- Trial name
- LOMBARD (NCT01804647)
- Testing
- No study treatments administered - blood draws only
- Where
- 4 sites in France, Spain and 1 more
- Volunteers
- 58 people
- Sponsor
- GeNeuro Innovation SAS
Multiple Sclerosis
EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis
The primary purpose is to determine the changes in gene expression induced by IFNb-1a (Rebif) and atorvastatin (Lipitor) combination therapy in patients with an isolated clinical syndrome suggestive of multiple sclerosis (MS), to…
- Trial name
- NCT00137176
- Testing
- Rebif
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of North Carolina, Chapel Hill
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
MS-ResearchBiomarkerS
This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- MS-ReBS (NCT05204459)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care
The Clinnova-Multiple Sclerosis (MS) study is part of the Clinnova program (NCT06526364; NCT06235684 and NCT05733702), which seeks to advance precision medicine and the digitalization of healthcare through high-quality…
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive, Clinically Isolated Syndrome, Primary Progressive Multiple Sclerosis
- Trial name
- Clinnova-MS (NCT07280871)
- Testing
- Cohort
- Where
- Luxembourg
- Volunteers
- 100 people
- Sponsor
- Luxembourg Institute of Health
Multiple Sclerosis
Gene Expression Profiles in Multiple Sclerosis (MS)
The purpose of this study is to test differences in RNA levels between Multiple Sclerosis (MS) patients and normal subjects. RNA provides a "message" from genes altered in diseases.
- Trial name
- NCT00704834
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Multiple Sclerosis, NMO Spectrum Disorder
China National Registry of Neuro-Inflammatory Diseases
Central nervous system (CNS) idiopathic inflammatory demyelinating diseases (IDD) are mainly diseases caused by autoimmune factors that result in CNS demyelination damage and loss.
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Clinically Isolated Syndrome, CNS Demyelinating Autoimmune Diseases
- Trial name
- CNRID (NCT05154370)
- Testing
- Intravenous steroid
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Beijing Tiantan Hospital
Multiple Sclerosis
Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis
The management of MS-patients requires treatment with immune-modifying or immune-suppressive agents to prevent new relapses and progression of disability.
- Trial name
- NCT01411514
- Testing
- Prednisone
- Where
- Switzerland
- Volunteers
- 27 people
- Sponsor
- Claudio Gobbi
Multiple Sclerosis
Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome
The primary objective is to assess the effect of treatment with glatiramer acetate (GA) compared to placebo on the time to conversion to CDMS, as determined by Poser criteria (the occurrence of the second clinical attack) during…
- Trial name
- PreCISe (NCT00666224)
- Testing
- Glatiramer Acetate (DB), Glatiramer Acetate (OL)
- Volunteers
- 481 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis
Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis
A key question in efforts to reduce symptoms and improve quality of life for multiple sclerosis (MS) patients is whether a therapeutic lifestyle (diet, stress reduction and exercise) is inferior to disease-modifying drug…
- Trial name
- NCT04009005
- Testing
- Therapeutic diet and lifestyle
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Terry L. Wahls